Program
GUB014295
A development code.
In AbbVie's pipeline, Long-Acting Amylin Analog
. Its studies are mostly in Overweight, led by AbbVie.
Furthest: phase 1, since Nov 8, 20231 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 10 open or running | phase 1since Nov 8, 2023 | Nov 8, 2023 | none ahead |
- Named in AbbVie’s own pipeline as
ABBV-295
, phase 2, as of Jul 30, 2026 (source).
Also a collaborator on its studies: quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 8, 2023First study: phase 1 study in OverweightFirst studyNCT06144684 · 76 enrolled · United Kingdom
TargetBeta
“Long-Acting Amylin Analog”the company's pipeline, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06144684Overweight · United Kingdom | 1 | Completed | Jan 5, 2026 | 76 |
How it is read
Names in the registry
- “GUB014295”, 1 entry
Codes read as this program: GUB014295.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.